Karaboué, A.; Collon, T.; Pavese, I.; Bodiguel, V.; Cucherousset, J.; Zakine, E.; Innominato, P.F.; Bouchahda, M.; Adam, R.; Lévi, F.
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers 2022, 14, 896.
https://doi.org/10.3390/cancers14040896
AMA Style
Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, Innominato PF, Bouchahda M, Adam R, Lévi F.
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers. 2022; 14(4):896.
https://doi.org/10.3390/cancers14040896
Chicago/Turabian Style
Karaboué, Abdoulaye, Thierry Collon, Ida Pavese, Viviane Bodiguel, Joel Cucherousset, Elda Zakine, Pasquale F. Innominato, Mohamed Bouchahda, René Adam, and Francis Lévi.
2022. "Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer" Cancers 14, no. 4: 896.
https://doi.org/10.3390/cancers14040896
APA Style
Karaboué, A., Collon, T., Pavese, I., Bodiguel, V., Cucherousset, J., Zakine, E., Innominato, P. F., Bouchahda, M., Adam, R., & Lévi, F.
(2022). Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers, 14(4), 896.
https://doi.org/10.3390/cancers14040896
